NCT05516056

ERAS After Cholecystectomy in Kigali, Rwanda

Status unknown NA Last updated 6 September 2022

What this trial tests

NA trial testing ERAS clinical pathway in ERAS in 50 participants. Status unknown.

Timeline

1 January 2022

Primary endpoint
31 December 2022

31 March 2023

Quick facts

Lead sponsor	Olivier Detry MD PhD
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	1 January 2022
Primary completion	31 December 2022
Estimated completion	31 March 2023
Sites	1 location across Rwanda

Drugs / interventions tested

• ERAS clinical pathway

Conditions studied

• ERAS — all drugs for ERAS →
• Gall Bladder Disease — all drugs for Gall Bladder Disease →

Sponsor

Olivier Detry MD PhD

Who can join

Adults 16 to 100, any sex, with ERAS or Gall Bladder Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Enhanced Recovery After Surgery (ERAS) pathway represents a peri-operative multimodal management aiming at a decrease in surgical aggression and an improved patient rehabilitation, in order to reduce postoperative morbidity, length of hospital stay and, as an important secondary consequence, overall costs. ERAS pathways have been successfully implemented in many surgical managements in the Western world, but very few data exist on ERAS in developing countries. This project aims at the prospective evaluation of ERAS pathway implementation in cholecystectomies in CHUK, Rwanda. The first 50 patients will be prospectively evaluated and compared to the last 50 patients who underwent cholecystectomy before ERAS pathway implementation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.